DGAP-News: MorphoSys AG / Key word(s): AGM/EGM Planegg/Munich, Germany, May 17, 2017 MorphoSys AG Reports Outcome of Annual General Meeting 2017 All Resolutions Proposed by the Company's Management Approved - The discharge of the members of the Management and Supervisory Boards with respect to the 2016 financial year - The appointment of PricewaterhouseCoopers AG as auditor for the 2017 financial year - Resolution on the creation of a new Authorized Capital 2017-I with the option to exclude statutory subscription rights; amendment to the Articles of Association - Resolution on the cancelation of Authorized Capital 2015-I and the creation of new Authorized Capital 2017-II with the option to exclude statutory subscription rights; amendment to the Articles of Association - Resolution on the election of Supervisory Board members At the Annual General Meeting 2017 of MorphoSys AG, 54.01 % of the current share capital were represented. "On behalf of the Management Board and the Company, I would like to thank our shareholders for their continued support and trust," commented Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG. More information on the Company's Annual General Meeting including the voting results on all agenda items can be found on http://www.morphosys.com/agm. About MorphoSys: HuCAL(R), HuCAL GOLD(R), HuCAL PLATINUM(R), CysDisplay(R), RapMAT(R), arYla(R), Ylanthia(R), 100 billion high potentials(R), Slonomics(R), Lanthio Pharma(R) and LanthioPep(R) are registered trademarks of the MorphoSys Group. This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned. MorphoSys AG Jochen Orlowski Alexandra Goller Tel: +49 (0) 89 / 899 27-404 Additional features: Document: http://n.eqs.com/c/fncls.ssp?u=NJWXYSTPSG Document title: Media Release 17.05.2017 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. |
Language: | English |
Company: | MorphoSys AG |
Semmelweisstr. 7 | |
82152 Planegg | |
Germany | |
Phone: | +49 (0)89 899 27-0 |
Fax: | +49 (0)89 899 27-222 |
E-mail: | investors@morphosys.com |
Internet: | www.morphosys.com |
ISIN: | DE0006632003 |
WKN: | 663200 |
Indices: | TecDAX |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
End of News | DGAP News Service |